What is claimed:

1. A compound having the formula I

$$\mathbb{R}^{6}$$
 \mathbb{R}^{7}
 \mathbb{R}^{8}
 \mathbb{R}^{8}

wherein X is O, S, CR¹, NR², or N;

wherein when Y is present, Y is CR9 or N and X is CR1 or N;

wherein when Y is not present, X is O, S, C(R¹)₂, or NR²;

wherein R¹-R⁹ are, independently, hydrogen, a branched or straight chain alkyl group, a hydroxyl group, an alkoxy group, a COOH group, a B(OH)₂ group, an alkyl substituted an amino group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, a thiol group, a thiol ether group, an amide group, an aldehyde group, a ketone group, an ester, an arakyl group, an aryl group, a nitrile group, a nitro, a halogen, a sulfo-oxo group, a sulfo-amide group, a phosphonate group, or a phosphate;

wherein the compound having the formula I has at least one B(OH)₂ group directly or indirectly bonded to the ring;

or the salt thereof,

wherein the compound is not 1-naphthalenyl boronic acid; 2-naphthalenyl boronic acid; 6-dimethylamino-2-naphthalenyl boronic acid boronic acid boronic acid; 6-amino-2-naphthalenyl boronic acid boronic acid; 8-quinolineboronic acid; benzo[b]thiophene-2-boronic acid; 2-(4-phenylboronic acid)-quinoline-4-carboxylic acid; N-Boc-4-amino-1-naphthalene boronic acid; 4-cyano-1-

naphthalenyl boronic acid; 6-((diphenylamino)-2-naphthalenyl) boronic acid; 5-bis-(phenylmethoxy)(ethyl)amino-2-naphthalenyl-boronic acid; 6-bis-(phenylmethoxy)(ethyl)amino-2-naphthalenyl-boronic acid; 6-((naphthalenylphenylamino)-2-naphthalenyl) boronic acid; 6-((1,1'-biphenyl-4-ylphenylamino)-2-naphthalenyl) boronic acid; 6-(2-naphthalenylphenylamino)-2-naphthalenyl) boronic acid; phenylmether ester of 4-borono-1-naphthalenyl carbamic acid; 6-cyano-1-naphthalenyl boronic acid; 4-(2,2-dimethyl-1-oxopropyl)amino-1-naphthalenyl boronic acid; 1-(diethylamino carbonyl)-2-naphthalenyl boronic acid; 4-(cyclopropylmethyl)propylamino-1-naphthalenyl boronic acid; 1-bis-(1-methylethyl)amino carbonyl)-2-naphthalenyl boronic acid; and 3-bis-(1-methylethyl)amino carbonyl)-4-methoxy-2-naphthalenyl boronic acid.

- 2. The compound of claim 1, wherein Y is CR⁹.
- 3. The compound of claim 2, wherein X is CR^1 .
- 4. The compound of claim 3, wherein R¹ is B(OH)₂.
- 5. The compound of claim 4, wherein at least one of R³-R⁹ is an alkyl substituted amino group.
- 6. The compound of claim 4, wherein R⁴ is an alkyl substituted amino group.
- 7. The compound of claim 4, wherein R⁴ is NMe₂.
- 8. The compound of claim 7, wherein R³ and R⁵-R⁹ are hydrogen.
- 9. The compound of claim 4, wherein R⁵ is an alkyl substituted amino group.
- 10. The compound of claim 4, wherein R⁵ is NMe₂
- 11. The compound of claim 10, wherein R³, R⁴, and R⁶-R⁹ are hydrogen.
- 12. The compound of claim 1, wherein Y is N and X is CR^1 .
- 13. The compound of claim 12, wherein R³ is B(OH)₂.

- 14. The compound of claim 13, wherein R⁴-R⁹ are hydrogen.
- 15. The compound of claim 12, wherein R⁴ is B(OH)₂.
- 16. The compound of claim 15, wherein R¹, R³, and R⁵-R⁸ are hydrogen.
- 17. The compound of claim 12, wherein R⁵ is B(OH)₂.
- 18. The compound of claim 17, wherein R³, R⁴, and R⁶-R⁹ are hydrogen.
- 19. The compound of claim 12, wherein R⁶ is B(OH)₂.
- 20. The compound of claim 19, wherein R^3-R^5 and R^7-R^9 are hydrogen.
- 21. The compound of claim 12, wherein R^7 is $B(OH)_2$.
- 22. The compound of claim 21, wherein R³-R⁶, R⁸, and R⁹ are hydrogen.
- 23. The compound of claim 12, wherein R⁸ is B(OH)₂.
- 24. The compound in any of claims 1-23, wherein the compound has a solubility of greater than 1 μ M in water.
- 25. The compound in any of claims 1-24, wherein the compound is the pharmaceutically acceptable salt or ester thereof.
- 26. A pharmaceutical composition comprising the compound in any of claims 1-25 and a pharmaceutically acceptable carrier.
- 27. A modified-macromolecule comprising a macromolecule having at least one compound having the formula II incorporated therein

$$\mathbb{R}^{6}$$
 \mathbb{R}^{7}
 \mathbb{R}^{8}
 \mathbb{R}^{8}

wherein X is O, S, CR¹, NR², or N;

wherein when Y is present, Y is CR⁹ or N and X is CR¹ or N;

wherein when Y is not present, X is O, S, C(R¹)₂, or NR²;

wherein R¹-R⁹ are, independently, hydrogen, a branched or straight chain alkyl group, a hydroxyl group, an alkoxy group, a COOH group, a B(OH)₂ group, an alkyl substituted amino group, an amino group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, a thiol group, a thiol ether group, an amide group, an aldehyde group, a ketone group, an ester, an arakyl group, an aryl group, a nitrile group, a nitro, a halogen, a sulfo-oxo group, a sulfo-amide group, a phosphonate group, or a phosphate;

wherein the compound having the formula II has at least one B(OH)₂ group directly or indirectly bonded to the ring;

or the salt thereof.

- 28. The modified-macromolecule of claim 27, wherein the macromolecule comprises an oligonucleotide, a nucleic acid or a metabolically stabilized analogue thereof, a polypeptide, a lipid, a dendrimer, a polymer, a glycoprotein, lipopolysaccharide, or a pharmaceutically-acceptable compound.
- 29. The modified-macromolecule of claim 27, wherein Y is CR⁹.
- 30. The modified-macromolecule of claim 29, wherein X is CR¹.
- 31. The modified-macromolecule of claim 30, wherein R¹ is B(OH)₂.
- 32. The modified-macromolecule of claim 31, wherein at least one of R³-R⁹ is an alkyl substituted amino group.
- 33. The modified-macromolecule of claim 31, wherein R⁴ is an alkyl substituted amino group.
- 34. The modified-macromolecule of claim 31, wherein R⁴ is NMe₂.

35. The modified-macromolecule of claim 34, wherein R³ and R⁵-R⁹ are hydrogen.

- 36. The modified-macromolecule of claim 31, wherein R⁵ is an alkyl substituted amino group.
- 37. The modified-macromolecule of claim 31, wherein R⁵ is NMe₂.
- 38. The modified-macromolecule of claim 37, wherein R³, R⁴, and R⁶-R⁹ are hydrogen.
- 39. The modified-macromolecule of claim 31, wherein R⁶ is an alkyl substituted amino group.
- 40. The modified-macromolecule of claim 31, wherein R⁶ is NMe₂.
- 41. The modified-macromolecule of claim 40, wherein R³-R⁵ and R⁷-R⁹ are hydrogen.
- 42. The modified-macromolecule of claim 27, wherein Y is N and Y is CR¹.
- 43. The modified-macromolecule of claim 42, wherein R³ is B(OH)₂.
- 44. The modified-macromolecule of claim 43, wherein R⁴-R⁹ are hydrogen.
- 45. The modified-macromolecule of claim 42, wherein R⁴ is B(OH)₂.
- 46. The modified-macromolecule of claim 45, wherein R¹, R³, and R⁵-R⁸ are hydrogen.
- 47. The modified-macromolecule of claim 42, wherein R⁵ is B(OH)₂.
- 48. The modified-macromolecule of claim 47, wherein R³, R⁴, and R⁶-R⁹ are hydrogen.
- 49. The modified-macromolecule of claim 42, wherein R⁶ is B(OH)₂.
- 50. The modified-macromolecule of claim 49, wherein R³-R⁵ and R⁷-R⁹ are hydrogen.
- 51. The modified-macromolecule of claim 42, wherein R⁷ is B(OH)₂.

52. The modified-macromolecule of claim 51, wherein R³-R⁶, R⁸, and R⁹ are hydrogen.

- 53. The modified-macromolecule of claim 42, wherein R⁸ is B(OH)₂.
- 54. The modified-macromolecule of claim 53, wherein R³-R⁷ and R⁹ are hydrogen.
- 55. The modified-macromolecule of claim 42, wherein at least one R³-R⁹ group is COOH.
- 56. The modified-macromolecule of claim 55, wherein at least one R³-R⁹ group is Z-B(OH)₂, where Z is an aryl group.
- 57. The modified-macromolecule of claim 56, wherein Z is a substituted or unbsubstituted phenyl ring.
- 58. The modified-macromolecule of claim 42, wherein R^4 is COOH and R^1 is p-phenyl-B(OH)₂.
- 59. The modified-macromolecule of claim 58, wherein R³ and R⁵-R⁹ are hydrogen.
- 60. The modified-macromolecule of claim 27, wherein Y is not present.
- 61. The modified-macromolecule of claim 60, wherein X is sulfur.
- 62. The modified-macromolecule of claim 61, wherein R^3 is $B(OH)_2$.
- 63. The modified-macromolecule of claim 61, wherein R⁴-R⁸ are hydrogen.
- 64. A method for detecting an analyte, comprising
 - (a) contacting the analyte with a compound having the formula II to produce a tagged analyte; and

$$R^{6}$$
 R^{7}
 R^{8}
 R^{8}

wherein X is O, S, CR¹, NR², or N;

wherein when Y is present, Y is CR⁹ or N and X is CR¹ or N; wherein when Y is not present, X is O, S, C(R¹)₂, or NR²;

wherein R¹-R⁹ are, independently, hydrogen, a branched or straight chain alkyl group, a hydroxyl group, an alkoxy group, a COOH group, a B(OH)₂ group, an alkyl substituted amino group, an amino group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, a thiol group, a thiol ether group, an amide group, an aldehyde group, a ketone group, an ester, an arakyl group, an aryl group, a nitrile group, a nitro, a halogen, a sulfo-oxo group, a sulfo-amide group, a phosphonate group, or a phosphate;

wherein the compound having the formula II has at least one B(OH)₂ group directly or indirectly bonded to the ring;

or the salt thereof; and

- (b) detecting the fluorescent emission produced from the tagged analyte.
- 65. A method for detecting an analyte, comprising
 - (a) contacting the analyte with a modified-macromolecule in any of claims 27-63 to produce a tagged analyte; and
 - (b) detecting the fluorescent emission produced from the tagged analyte.

66. The method of claim 64 or 65, wherein the analyte comprises a natural or synthetic oligonucleotide, a natural or modified/blocked nucleotide/nucleoside, a nucleic acid (DNA) or (RNA), a peptide comprising natural or modified/blocked amino acid, an antibody, a parasite, a hapten, a biological ligand, a protein membrane, a lipid membrane, a small pharmaceutical molecule, a virus, a bacterium, or a cell.

- 67. The method of claim 64 or 65, wherein the analyte is a carbohydrate.
- 68. The method of claim 67, wherein the carbohydrate is fructose, galactose, glucose, mannose, arabinose, sorbitol, tagatose, lactose, fucose, sialyl Lewis X, sialyl Lewis a, Lewis Y, Lewis X, blood group antigens, or an oligosaccharide that is part of a glycoprotein, a glycolipid, a lipopolysaccharide, a stage specific antigen, or a cancer carbohydrate-containing biomarker.
- 69. The method of claim 64 or 65, wherein the analyte is detected in vivo.
- 70. The method of claim 64 or 65, wherein the analyte is detected in vitro.
- 71. The method of claim 64 or 65, wherein the analyte is blood sugar from a blood sample of a subject.
- 72. The method of claim 64 or 65, wherein the analyte is a glycoprotein.
- 73. The method of claim 72, wherein the glycoprotein is immobilized on a gel.
- 74. The method of claim 64 or 65, wherein the analyte is a lipposaccharide produced by bacteria.
- 75. The method of claim 64, wherein Y is CR⁹.
- 76. The method of claim 75, wherein X is CR¹.
- 77. The method of claim 76, wherein R¹ is B(OH)₂.
- 78. The method of claim 77, wherein at least one of R³-R⁹ is an alkyl substituted amino group.

79. The method of claim 78, wherein R⁴ is an alkyl substituted amino group.

- 80. The method of claim 78, wherein R⁴ is NMe₂
- 81. The method of claim 80, wherein R³ and R⁵-R⁹ are hydrogen.
- 82. The modified-macromolecule of claim 78, wherein R⁵ is an alkyl substituted amino group.
- 83. The method of claim 78, wherein R⁵ is NMe₂.
- 84. The method of claim 83, wherein R^3 , R^4 , and R^6 - R^9 are hydrogen.
- 85. The method of claim 78, wherein R⁶ is an alkyl substituted amino group.
- 86. The method of claim 78, wherein R⁶ is NMe₂.
- 87. The method of claim 86, wherein R^3-R^5 and R^7-R^9 are hydrogen.
- 88. The method of claim 64, wherein Y is N and Y is CR¹.
- 89. The method of claim 88, wherein R³ is B(OH)₂.
- 90. The method of claim 89, wherein R⁴-R⁹ are hydrogen.
- 91. The method of claim 88, wherein R⁴ is B(OH)₂.
- 92. The method of claim 91, wherein R¹, R³, and R⁵-R⁸ are hydrogen.
- 93. The method of claim 88, wherein R⁵ is B(OH)₂.
- 94. The method of claim 93, wherein R³, R⁴, and R⁶-R⁹ are hydrogen.
- 95. The method of claim 88, wherein R⁶ is B(OH)₂.
- 96. The method of claim 95, wherein R^3-R^5 and R^7-R^9 are hydrogen.
- 97. The method of claim 88, wherein R^7 is $B(OH)_2$.
- 98. The method of claim 97, wherein R³-R⁶, R⁸, and R⁹ are hydrogen.
- 99. The method of claim 88, wherein R^8 is $B(OH)_2$.
- 100. The method of claim 99, wherein R³-R⁷ and R⁹ are hydrogen.

- 101. The method of claim 88, wherein at least one R³-R⁹ group is COOH.
- 102. The method of claim 101, wherein at least one R^3 - R^9 group is Z- $B(OH)_2$, where Z is an aryl group.
- 103. The method of claim 102, wherein Z is a substituted or unbsubstituted phenyl ring.
- 104. The method of claim 88, wherein R^4 is COOH and R^1 is p-phenyl-B(OH)₂.
- 105. The modified-macromolecule of claim 104, wherein R³ and R⁵-R⁹ are hydrogen.
- 106. The method of claim 105, wherein Y is not present.
- 107. The method of claim 106, wherein X is sulfur.
- 108. The method of claim 107, wherein R³ is B(OH)₂.
- 109. The method of claim 108, wherein R⁴-R⁸ are hydrogen.
- 110. An article comprising the modified macromolecule of claim 27.
- 111. An article comprising the compound having the formula II

$$\mathbb{R}^{6}$$
 \mathbb{R}^{7}
 \mathbb{R}^{8}
 \mathbb{R}^{8}

wherein X is O, S, CR1, NR2, or N;

wherein when Y is present, Y is CR9 or N and X is CR1 or N;

wherein when Y is not present, X is O, S, C(R¹)₂, or NR²;

wherein R¹-R⁹ are, independently, hydrogen, a branched or straight chain alkyl

group, a hydroxyl group, an alkoxy group, a COOH group, a B(OH)₂ group, an alkyl substituted amino group, an amino group, a hydroxyalkyl group, an alkoxyalkyl group, an aminoalkyl group, a thiol group, a thiol ether group, an amide group, an aldehyde group, a ketone group, an ester, an arakyl group, an aryl group, a nitrile group, a nitro, a halogen, a sulfo-oxo group, a sulfo-amide group, a phosphonate group, or a phosphate;

wherein the compound having the formula II has at least one B(OH)₂ group directly or indirectly bonded to the ring;

or the salt thereof.

112. The article of claims 110 or 111, wherein the article comprises a sensor chip or microplate.